Agendia Presents Data Supporting MammaPrint's Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference

HUNTINGTON BEACH, California, and AMSTERDAM, The Netherlands, March
11 (ots/PRNewswire) -- Agendia, a world leader in molecular cancer
diagnostics, today announced that leading researchers from Agendia
and the Netherlands Cancer Institute will present data from multiple
studies at the 2009 St.Gallen Breast Cancer Conference. The St.
Gallen Breast Cancer Conference, one of the premiere conferences in
breast cancer research worldwide, takes place March 11th-14th, 2009
in St.Gallen, Switzerland.

The study results further underpin the predictive and prognostic
power of Agendia's breast cancer recurrence test, MammaPrint(R) and
will be discussed at the following poster sessions:

Thursday, 12 March 2009

Poster 0063

Comparison of MammaPrint and TargetPrint Results with Clinical
Parameters in German Patients (PATH) with Early Stage Breast Cancer

G. Kunz, T. Dimpfl, C. Jakisch, R. Buttner, F. A. de Snoo, O.
Krijgsman, E. van Lienen, A. Glas, and R. Bender.

Thursday, 12 March 2009

Poster 0071

The 70 Gene-MammaPrint Profile Allows to Identify a Subgroup of
Good-Prognostic Patients with Primary Breast Cancer and 4-9 Positive
Lymph Nodes

M. Saghatchian, S. Mook, G. Pruneri, G. Viale, A. Glas, I.
Eekhout, M. Knauer, and LJ van 't Veer.

Thursday, 12 March 2009

Poster 0072

The 70-gene MammaPrint Prognosis Signature for Optimal Risk
Stratification in Endocrine Responsive Breast Cancer

M Knauer, EJT Rutgers, S Mook, F Cardoso, MJ van de Vijver, G
Viale, AM Glas, M. Saghatchian, M Kok, JM Bueno-de-Mesquita, SC Linn
and LJ van 't Veer.

Thursday, 12 March 2009

Poster 0073

The 70-gene MammaPrint Signature Is Predictive for
Chemotherapy Benefit in Early Breast Cancer

M Knauer, ME Sraver, EJT Rutgers, RA Bender, F Cardoso, S Mook,
MJ van de Vijver, M. Saghatchian, RHT Koornstra, JM
Bueno-de-Mesquita, S Rodenhuis, SC Linn and LJ van 't Veer.

Thursday, 12 March 2009

Poster 0074

Early Prognosis Prediction: MammaPrint on Core-needle biopsies

F. de Snoo, A. Glas, A. Floore, J. Mayordomo, A. Modollel, C.
Rolfo, LJ van 't Veer, E. Rutgers, S. Rodenhuis, and R. Bender.

Thursday, 12 March 2009

Poster 0075

Use of the Genomic Test MammaPrint in Daily Clinical Practice
to Assist in Risk Stratification of Young Breast Cancer Patients

G. Kunz, A. Glas and F. de Snoo, I. Simon.

About MammaPrint(R)

MammaPrint is the first 'in vitro diagnostic multivariate index
assay' (IVDMIA) cleared by the U.S. Food and Drug Administration
(FDA). FDA clearance requires clinical and analytical validation and
reporting systems to ensure patient safety issues are addressed.
Highly accurate, MammaPrint identifies patients with early
metastasis-those patients who are likely to develop metastases within
five years following surgery. Several authoritative studies have
shown that chemotherapy particularly reduces early metastasis risk.
In planning treatment, the MammaPrint test result provides a doctor
with a clear rationale to assess the benefit of chemotherapy in
addition to other clinical information and pathology tests.

All MammaPrint tests are conducted in Agendia's CLIA-accredited
service laboratory. Breast cancer recurrence assays currently
marketed by other manufacturers have not been subject to the rigorous
FDA clearance process.

About Agendia

Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized
treatments within reach of patients. Building on a cutting edge
genomics platform for tumor gene expression profiling, the company's
tests aim to help physicians more accurately tailor cancer
treatments. The company markets four products, with several new
genomic tests under development. In addition, Agendia collaborates
with pharmaceutical companies to develop highly effective
personalized drugs in the area of oncology. Agendia was awarded the
2008 North American Oncology Clinical Diagnostics Healthcare
Innovation Award by Frost & Sullivan. Agendia is based in Huntington
Beach, California, and in Amsterdam, The Netherlands.

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media Contacts: Hans Herklots, Agendia, +31-20-462-1557 Office,
+31-620-083-509 Mobile, hans.herklots@agendia.com. Valerie Delva,
Ricochet Public Relations, +1-212-679-3300 x131 Office,
+1-917-975-3191 Mobile, vdelva@ricochetpr.com